Skip to main content
. 2015 Oct 12;47(6):2082–2090. doi: 10.3892/ijo.2015.3196

Figure 6.

Figure 6

Survival curve of patients who expressed high or low levels of Helios in CD4+ Foxp3+ T cells. (A) Recurrence-free survival (RFS) and (B) overall survival (OS) by peripheral CD4+ Foxp3+ T cells. (C) RFS and (D) OS by CD4+ Foxp3+ T cells in tumor sites.